• Molecular NameItraconazole
  • SynonymITC; ITCZ; ITR; Itraconazol [Spanish]; itraconazole; Itraconazolum [Latin]; ITZ
  • Weight705.647
  • Drugbank_IDDB01167
  • ACS_NO84625-61-6
  • Show 3D model
  • LogP (experiment)5.66
  • LogP (predicted, AB/LogP v2.0)5.72
  • pka3.7
  • LogD (pH=7, predicted)5.71
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-6.34
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors0
  • No.of HBond Acceptors12
  • No.of Rotatable Bonds11
  • TPSA100.79
  • StatusFDA approved
  • AdministrationOral and i.v. (US), Oral only (UK)
  • PharmacologyA triazole antifungal agent that is prescribed to patients with fungal infections.
  • Absorption_value80.0
  • Absorption (description)Itraconazole is slowly but well absorbed after oral administration with peak concentrations reached in approx. 4 h. Absorption is enhanced in the presence of food and in an acidic intragastric environment.
  • Caco_2N/A
  • Bioavailability55.0
  • Protein binding99.8
  • Volume of distribution (VD)14 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMetabolized predominantly by CYP3A4 to an active metabolite, hydroxyitraconazole, and other sequential metabolites.
  • Half life20 h (following a 100 mg single dose); increases to 30 h on multiple dosing.
  • Excretion3 to 18 % is excreted in the faeces as unchanged drug.
  • Urinary Excretion<1
  • Clerance23 ml/min/kg
  • ToxicityThe serum toxic concentration is 6 mg/L (sum of itraconazole and its hydroxy metabolite).
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=46.4 (iv)